Glenmark Pharma Gets Usfda Nod For Prostate Cancer Treatment Drug

Drug Firm Glenmark Pharmaceuticals On Thursday Said It Has Received Final Approval From The Us Health Regulator For Abiraterone Acetate Tablets, Used To Treat Prostate Cancer. The Approved Product Is A Generic Version Of Zytiga Tablets, 250 Mg, Of Janssen Biotech."Glenmark Pharmaceuticals Inc., Usa Has Been Granted Final Approval By The United States Food & Drug Administration (Usfda) For Abiraterone Acetate Tablets Usp, 250 Mg," The Company Said In A Regulatory Filing.Quoting Iqvia Sales Data For The 12 Month Period Ending August 2019, Glenmark Said The Zytiga Tablets, 250 Mg Market Achieved Annual Sales Of Approximately $794.1 Million.Glenmark'S Current Portfolio Consists Of 162 Products Authorised For Distribution In The Us Marketplace And 46 Anda'S Pending Approval With The Usfda.Shares Of Glenmark Pharma Were Trading 0.15 Per Cent Higher At Rs 286.00 Apiece On The Bse.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!